Johnson & Johnson Stock Deutsche Boerse AG

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Deutsche Boerse AG 01:53:04 2024-05-13 pm EDT 5-day change 1st Jan Change
139.6 EUR +0.46% Intraday chart for Johnson & Johnson +1.41% -1.51%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2024 * 88.37B 81.93B Sales 2025 * 90.78B 84.16B Capitalization 364B 337B
Net income 2024 * 22.04B 20.43B Net income 2025 * 23.09B 21.41B EV / Sales 2024 * 4.04 x
Net cash position 2024 * 7B 6.49B Net cash position 2025 * 21.07B 19.54B EV / Sales 2025 * 3.78 x
P/E ratio 2024 *
16.8 x
P/E ratio 2025 *
15.9 x
Employees 131,900
Yield 2024 *
3.19%
Yield 2025 *
3.33%
Free-Float 77.07%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Johnson & Johnson

1 day+0.46%
1 week+1.41%
Current month+2.35%
1 month+0.32%
3 months-4.28%
6 months+1.06%
Current year-1.51%
More quotes
1 week
137.82
Extreme 137.82
139.78
1 month
134.00
Extreme 134
142.00
Current year
134.00
Extreme 134
150.20
1 year
134.00
Extreme 134
160.40
3 years
133.14
Extreme 133.14
178.00
5 years
104.00
Extreme 104
178.00
10 years
72.84
Extreme 72.835
178.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 88-12-31
Director of Finance/CFO 57 97-12-31
Chief Tech/Sci/R&D Officer 58 19-11-04
Members of the board TitleAgeSince
Director/Board Member 70 19-04-24
Director/Board Member 72 14-06-18
Director/Board Member 70 09-10-21
More insiders
Date Price Change Volume
24-05-13 139.6 +0.46% 823
24-05-10 138.9 -0.13% 1,575
24-05-09 139.1 +0.20% 255
24-05-08 138.8 +0.29% 155
24-05-07 138.4 +0.58% 1,513

Delayed Quote Deutsche Boerse AG, May 13, 2024 at 01:53 pm EDT

More quotes
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
151.2 USD
Average target price
173.3 USD
Spread / Average Target
+14.58%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW